Galectin-1-producing mesenchymal stem cells restrain the proliferation of T lymphocytes from patients with systemic lupus erythematosus

References

• Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):ITC81–ITC96. doi: 10.7326/AITC202006020.
   PubMed Web of Science ®Google Scholar
• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi: 10.1056/NEJMra1100359.
   PubMed Web of Science ®Google Scholar
• Moulton VR, Suarez-Fueyo A, Meidan E, et al. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med. 2017;23(7):615–635. doi: 10.1016/j.molmed.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332–2343. doi: 10.1016/S0140-6736(19)30237-5.
   PubMed Web of Science ®Google Scholar
• Ji S, Guo Q, Han Y, et al. Mesenchymal stem cell transplantation inhibits abnormal activation of Akt/GSK3β signaling pathway in T cells from systemic lupus erythematosus mice. Cell Physiol Biochem. 2012;29(5-6):705–712. doi: 10.1159/000178590.
   PubMedGoogle Scholar
• Cipriani P, Ruscitti P, Di Benedetto P, et al. Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. Cytotherapy. 2015;17(7):832–849. doi: 10.1016/j.jcyt.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Lv FJ, Tuan RS, Cheung KM, et al. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408–1419. doi: 10.1002/stem.1681.
   PubMed Web of Science ®Google Scholar
• Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019;76(17):3323–3348. doi: 10.1007/s00018-019-03125-1.
   PubMed Web of Science ®Google Scholar
• Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W, et al. Role of stem cells in pathophysiology and therapy of spondyloarthropathies-new therapeutic possibilities? Int J Mol Sci. 2017;19(1):80. doi: 10.3390/ijms19010080.
   PubMed Web of Science ®Google Scholar
• Choi EW, Lee M, Song JW, et al. Mesenchymal stem cell transplantation can restore lupus disease-associated miRNA expression and Th1/Th2 ratios in a murine model of SLE. Sci Rep. 2016;6(1):38237. doi: 10.1038/srep38237.
   PubMedGoogle Scholar
• Wang D, Sun L. Stem cell therapies for systemic lupus erythematosus: current progress and established evidence. Expert Rev Clin Immunol. 2015;11(6):763–769. doi: 10.1586/1744666X.2015.1037741.
   PubMed Web of Science ®Google Scholar
• Deng D, Zhang P, Guo Y, et al. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436–1439. doi: 10.1136/annrheumdis-2017-211073.
   PubMed Web of Science ®Google Scholar
• Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423–431. doi: 10.1038/cmi.2015.89.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang YU, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493–507. doi: 10.1038/s41581-018-0023-5.
   PubMed Web of Science ®Google Scholar
• Gieseke F, Böhringer J, Bussolari R, et al. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood. 2010;116(19):3770–3779. doi: 10.1182/blood-2010-02-270777.
   PubMed Web of Science ®Google Scholar
• Morel L. Immunometabolism in systemic lupus erythematosus. Nat Rev Rheumatol. 2017;13(5):280–290. doi: 10.1038/nrrheum.2017.43.
   PubMed Web of Science ®Google Scholar
• Ma K, Du W, Wang X, et al. Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci. 2019;20(23):6021. doi: 10.3390/ijms20236021.
   PubMed Web of Science ®Google Scholar
• Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1–13. doi: 10.1016/j.jaut.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, et al. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043–1053. doi: 10.1080/1744666X.2018.1538789.
   PubMed Web of Science ®Google Scholar
• Gatto M, Zen M, Iaccarino L, et al. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30–48. doi: 10.1038/s41584-018-0133-2.
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182. doi: 10.1186/s13287-019-1287-9.
   PubMedGoogle Scholar
• Luque-Campos N, Contreras-López RA, Jose Paredes-Martínez M, et al. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response. Front Immunol. 2019;10:798. doi: 10.3389/fimmu.2019.00798.
   PubMed Web of Science ®Google Scholar
• Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies. Int J Mol Sci. 2020;21(22):8662. doi: 10.3390/ijms21228662.
   PubMed Web of Science ®Google Scholar
• Zhou T, Liao C, Li HY, et al. Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. Stem Cell Res Ther. 2020;11(1):48. doi: 10.1186/s13287-019-1538-9.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Tsokos GC, Moulton VR. Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front Immunol. 2018;9:1088. doi: 10.3389/fimmu.2018.01088.
   PubMed Web of Science ®Google Scholar
• de Witte SF, Franquesa M, Baan CC, et al. Toward development of iMesenchymal stem cells for immunomodulatory therapy. Front Immunol. 2015;6:648. doi: 10.3389/fimmu.2015.00648.
   PubMed Web of Science ®Google Scholar
• Appleman LJ, Berezovskaya A, Grass I, et al. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol. 2000;164(1):144–151. doi: 10.4049/jimmunol.164.1.144.
   PubMed Web of Science ®Google Scholar
• Harrell CR, Fellabaum C, Jovicic N, et al. Molecular mechanisms ­responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019;8(5):467. doi: 10.3390/cells8050467.
   PubMed Web of Science ®Google Scholar
• Dhirapong A, Lleo A, Leung P, et al. The immunological potential of galectin-1 and -3. Autoimmun Rev. 2009;8(5):360–363. doi: 10.1016/j.autrev.2008.11.009.
   PubMed Web of Science ®Google Scholar
• Liu SD, Lee S, La Cava A, et al. Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus. 2011;20(5):473–484. doi: 10.1177/0961203310388444.
   PubMed Web of Science ®Google Scholar
• Hornung Á, Monostori É, Kovács L. Systemic lupus erythematosus in the light of the regulatory effects of galectin-1 on T-cell function. Lupus. 2017;26(4):339–347. doi: 10.1177/0961203316686846.
   PubMed Web of Science ®Google Scholar